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A deﬁ ning moment in the global AIDS response has 
been reached. The discourse is no longer about HIV 
prevention or HIV treatment; it is now about HIV control 
through the implementation of antiretrovirals as key 
components of combination interventions. Barely a year 
ago, visions of HIV control would have been considered 
far-fetched. The impetus for this change in mindset, 
which has been building since the XVIII International 
AIDS Conference in Vienna last year, emanates from 
the compelling evidence that antiretroviral drugs 
prevent HIV infection in the general heterosexual 
population, which is released this week and presented 
at the 6th International AIDS Society Conference on HIV 
Pathogenesis, Treatment and Prevention in Rome by the 
Partners PrEP1 and Botswana TDF22 trials.
The Partners PrEP trial,1 involving 4758 HIV discordant 
couples from Kenya and Uganda, found that daily 
oral tenofovir disoproxil fumarate (TDF) and TDF-
emtricitabine reduced HIV transmission by 62% 
and 73%, respectively. The Bostwana TDF2 trial,2 in 
1200 heterosexual men and women from the general 
population, found that daily oral TDF-emtricitabine 
reduced HIV transmission by 63%. These ﬁ ndings follow 
close on the heels of the CAPRISA 004 trial3 of tenofovir 
gel, the iPrEX trial4 of oral TDF-emtricitabine in men 
who have sex with men, and the HPTN 052 trial5 of early 
antiretroviral treatment as HIV prevention. Importantly, 
these new ﬁ ndings ﬁ ll a critical gap in HIV prevention 
with a readily available antiretroviral approach to prevent 
heterosexual transmission in both men and women 
(ﬁ gure). Women beneﬁ t from a new prevention option 
under their control, which is particularly important for 
those not assured of their partner’s ﬁ delity or willingness 
to use a condom. The hope these studies add to HIV 
prevention is further bolstered by the recent step taken 
by the pharmaceutical company Gilead Sciences Inc to 
lodge TDF and emtricitabine with the UNITAID patent 
pool,12 thus enabling lower cost versions of the drugs to 
be manufactured and thereby facilitating wider access in 
poor countries.
There is now no doubt that antiretroviral drugs 
prevent HIV infection. However, important scientiﬁ c 
questions remain. Does the inclusion of emtricitabine in 
pre-exposure prophylaxis (PrEP) formulations provide 
suﬃ  cient additional beneﬁ t to warrant the additional 
costs and side-eﬀ ects? Are levels of eﬀ ectiveness and 
safety similar for daily use and use-with-sex of PrEP? 
Do the safety, eﬀ ectiveness, cost, and acceptability 
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Figure: HIV prevention technologies shown to be eﬀ ective in reducing HIV incidence in randomised controlled trials1––11 
PrEP=Pre-exposure prophylaxis. *Meta-analysis of circumcision trials.
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proﬁ les of oral and topical PrEP merit implementation 
of both formulations? Does PrEP lead to masking of HIV 
acquisition that is then revealed once PrEP is withdrawn? 
Can the new results be generalised to the type of hyper-
endemic settings (HIV incidence more than 5% per 
annum) where the FEMPrEP trial13 was done? Since 
inadequate drug levels may not have been responsible 
for the lack of eﬀ ectiveness observed in the FEMPrEP 
study,14 the search for an explanation for this intriguing 
and contrary result needs to be pursued with vigour. 
There are also many practical questions about 
implementation: how to increase uptake of HIV testing;15 
how often to monitor HIV status in people on PrEP; how 
to achieve high coverage in those at highest risk; how 
to maintain high levels of adherence; how to reduce 
the risk of migration away from condoms (behavioural 
disinhibition); and how to monitor the risk of drug 
resistance. While attempts are being made to obtain 
data to address these questions and to generate data 
to guide eﬀ ective implementation, the development of 
normative guidance by WHO/UNAIDS and submissions 
for regulatory approvals of TDF and TDF-emtricitabine 
as PrEP for HIV infection are key next steps. 
As antiretroviral drugs take a key role in the global eﬀ ort 
to control the HIV epidemic, there is much to be learned 
from the contraceptive ﬁ eld where multiple technologies, 
approaches, formulations, and dosing options were 
developed to enable and maximise user choice and 
increase levels of uptake, coverage, and adherence and 
thereby improve the public health impact. 
Beyond the questions of implementation, the future 
scientiﬁ c challenge looming large for PrEP is ﬁ nding a 
drug or class of drugs with a resistance proﬁ le that does 
not interfere with existing ﬁ rst-line and second-line AIDS 
treatment. Treatment of HIV-positive people for HIV 
prevention and PrEP and microbicides for HIV-negative 
people are two sides of the same coin, and cannot be 
viewed in isolation from each other. Although research 
on treatment for prevention, PrEP, and microbicides 
has mostly occurred in separate silos, their ﬁ ndings 
converge into a single focus in HIV prevention and 
necessitate guidance on how to use all three strategies 
synergistically for maximum beneﬁ t depending on 
the nature of the HIV epidemic. There is no magic 
bullet for the HIV epidemic. Treatment for prevention 
will be dependent on the extent to which couples 
establish their HIV status, whether the HIV-positive 
partner in a discordant couple adheres to therapy, and 
whether the HIV-negative partner maintains ﬁ delity 
within the partnership. PrEP will be dependent on the 
extent to which people seek to establish and regularly 
monitor their HIV status and those on PrEP adhere to 
their regimen and clinical monitoring. Hyper-endemic 
communities, such as those in South Africa where HIV 
prevalence in the community is high, may require both 
interventions jointly and synergistically: treatment of 
people infected with HIV to reduce risk of transmission 
within the discordant couple, and PrEP to reduce the 
HIV-negative partner’s risk of HIV acquisition from 
outside partners.
Therein lie the three most complex policy, 
implementation, ﬁ scal, and ethical challenges generated 
by these new ﬁ ndings. First, how to scale up HIV 
testing, a key prerequisite in settings with stigma and 
discrimination. Second, how to extend antiretrovirals 
for both treatment and prevention when many of 
Africa’s health systems are already struggling to cope 
with patients with AIDS and are not able to initiate 
antiretroviral therapy in everyone who currently needs 
it for their survival. Third, in the context of limited 
resources how best to ration and prioritise the limited 
available implementation capacity.
In this deﬁ ning moment in the response to HIV, a 
global commitment to increased ﬁ nancial resources for 
implementation, health systems strengthening, and 
greater implementation eﬃ  ciency is imperative. Anything 
less will crush the hope and promise that antiretroviral 
drugs can change the course of the HIV epidemic.
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